6375-20-8

Usage

InChI:InChI=1/C9H12N2O/c1-6-5-8(11-7(2)12)3-4-9(6)10/h3-5H,10H2,1-2H3,(H,11,12)

Upstream product

• 108-24-7 acetic anhydride 
• 95-70-5 2-methyl-p-phenylenediamine 
• 95-80-7 4-methylbenzene-1,3-diamine 
• 106-50-3 1,4-phenylenediamine 
• 823-40-5 2,6-toluenediamine 
• 355809-03-9 2,2,2-trifluoro-N-(2-methyl-4-nitrophenyl)acetamide 
• 99-52-5 2-methyl-4-nitro-benzenamine 
• 51366-39-3 4-acetamido-2-methylnitrobenzene 
• 611-05-2 4-nitro-3-methylaniline 
• 99584-85-7 3-methyl-4-nitro benzamide 

Downstream Products

• 102590-70-5 N-(7-methyl-2,3-diphenyl-indol-5-yl)-acetamide 
• 720699-25-2 acetic acid-(4-amino-5-methyl-2-nitro-anilide) 
• 25917-89-9 4-amino-3-nitro-6-methylaniline 
• 154150-99-9 N,N'-(2-methyl-5-nitro-p-phenylene)-bis-acetamide 
• 104479-02-9 C₁₄H₁₈N₄O₅ 

Relevant academic research and scientific papers

COMPOUNDS FOR INHIBITING TNIK AND MEDICAL USES THEREOF

The present disclosure provides the compound having inhibitory property against TNIK having a specific chemical structure or its pharmaceutically acceptable salt. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating or preventing cancer. The present disclosure also provides a method of treatment or prevention of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment or prevention.

HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS

The present invention is directed to heterocyclic compounds which are antagonists of CGRP receptors and may be useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents

The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.

Quinone Imine Route to Benzimidazol-2-ylcarbamates. Part 1. Synthesis of Open-chain and Cyclic 5-Acylamino Derivatives.

The synthesis of the N',N''-bismethoxycarbonyl-N-(4-acylaminophenyl)guanidines (4) and (7) is described.Oxidation of these with LTA has led to the benzimidazol-2-ylcarbamates. (8), (9) and (10) through a regiospecific cyclisation of quinone imine intermediates.If the acylamino group is part of a ring, the yield of benzimidazoles (15) increases with the size of the lactam ring.The direction of ring closure may be controlled by electronic and steric factors.

2-[(Aminophenyl and amidophenyl)amino]-1-azacycloalkanes having antidiarrheal activity

This invention relates to the novel use of certain aromatic substituted amidines as antidiarrheals.

Process for the monoacylation of an aromatic primary diamine

A process for the monoacylating of an aromatic primary diamine containing no anionic water-solubilizing group, preferably m-phenylene or p-phenylenediamine, which comprises reacting an acylating agent in aqueous medium with a mineral acid salt, preferably the hydrochloric acid salt, of the diamine wherein the reaction mixture is maintained at a pH of from 1.5 to 3.5 during the addition and reaction of the acylating agent.